<?xml version="1.0" encoding="UTF-8"?>
<ref id="ppat.1007716.ref012">
 <label>12</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Saez-Llorens</surname>
   <given-names>X</given-names>
  </name>, 
  <name>
   <surname>Tricou</surname>
   <given-names>V</given-names>
  </name>, 
  <name>
   <surname>Yu</surname>
   <given-names>D</given-names>
  </name>, 
  <name>
   <surname>Rivera</surname>
   <given-names>L</given-names>
  </name>, 
  <name>
   <surname>Jimeno</surname>
   <given-names>J</given-names>
  </name>, 
  <etal>et al</etal> (
  <year>2018</year>) 
  <article-title>Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study</article-title>. 
  <source>Lancet Infect Dis</source>
  <volume>18</volume>: 
  <fpage>162</fpage>–
  <lpage>170</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S1473-3099(17)30632-1</pub-id>
  <?supplied-pmid 29122463?>
  <pub-id pub-id-type="pmid">29122463</pub-id>
 </mixed-citation>
</ref>
